Czech Atherosclerosis Society Guidelines for the Diagnosis and Treatment of Dyslipidemias in Adults

Česká verzia

Authors: H. Vaverková ¹; V. Soška ²; H. Rosolová ³; R. Češka ⁴; R. Cífková ⁵; T. Freiberger ⁶; J. Piťha ⁷; R. Poledne ⁷; T. Štulc ⁴; Z. Urbanová ⁸; M. Vráblík ⁴
Authors place of work: III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc. ¹; Oddělení klinické biochemie FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Soška, CSc. ²; Centrum preventivní kardiologie, II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta doc. MUDr. Jan Filipovský, CSc. ³; III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ⁴; Pracoviště preventivní kardiologie Institutu klinické a experimentální medicíny Praha, přednostka doc. MUDr. Renata Cífková, CSc. ⁵; Genetická laboratoř, Centrum kardiovaskulární a transplantační chirurgie, Brno, ředitel prof. MUDr. Jan Černý, CSc. ⁶; Laboratoř pro výzkum aterosklerózy Institutu klinické a experimentální medicíny Praha, vedoucí MUDr. Jan Piťha, CSc. ⁷; Klinika dětského a dorostového lékařství 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Josef Hoza, CSc. ⁸
Published in the journal: Vnitř Lék 2007; 53(2): 181-197
Category: Guidelines

Summary

The present guidelines are based on the recommendations published in 2005 entitled “Prevention of Cardiovascular Diseases in Adulthood” summarizing the conclusions of nine Czech medical societies and agree with them in the assessment of individual risks of mortality from cardiovascular disease (CVD) according to SCORE tables. They reflect new research data in pathophysiology of dyslipidemias (DLP) and particularly the results of recent clinical trials of lipid-lowering therapy and their meta-analyses. They establish priorities for the screening and management of DLP, present suitable diagnostic methods, additional investigations of potential use in risk assessment, including some emerging risk factors and detection of sub-clinical atherosclerosis in persons in a moderate-risk category. Major changes include a lower LDL-cholesterol treatment target (< 2.0 mmol/L for all CVD individuals) and a possible use of apolipoprotein B as a secondary target in selected persons (< 0.9 g/L in high risk without CVD, < 0.8 g/L for CVD patients) and nonHDL-cholesterol (< 3.3 mmol/L in high risk without CVD, < 2.8 mmol/L for CVD patients). Therapy of individual DLP phenotypes (monotherapy and combination therapy) as well as basic principles for control examination at lipid-lowering medication are described. Recommended therapeutic lifestyle changes are shown. Enclosed are five annexes: DLP diagnosis; causes of secondary DLP; additional investigations of potential use in risk stratification; familial hypercholesterolemia; list of recommended foods; two variants of SCORE tables for risk assessment for the Czech Republic; the scheme of recommended procedures and treatment algorithm in DLP asymptomatic individuals.

Key words:
dyslipidemias - guidelines - LDL-cholesterol - apolipoprotein B - cardiovascular diseases

Zdroje

1. Cífková R, Býma S, Češka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005; 51: 1021–1036.

2. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500.

3. Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219.

4. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19(Suppl A): A2–A11.

5. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–364.

6. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-anylysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267–1278.

7. Castelli, WP, Garrison RJ, Wilson PWF et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256: 2835.

8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994: 334: 1383–1389.

9. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.

10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

11. Collins R, Armitage J, Parish S et al. (Heart Protection Study Collaborative Group). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet 2003; 361: 2005–2016.

12. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.

13. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.

14. Nissen SE, Tuzcu EM, Schoenhagen P et al. (REVERSAL Investigators). Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071–1080.

15. Sever PS, Dahlof B, Poulter NR et al. (ASCOT investigators). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.

16. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

17. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of Very High–Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 2006; 295(13):1556–1565.

18. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–2033.

19.Walldius G, Jungner I The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006; 259: 493–519.

20. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in quiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006; 259: 247–258.

21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

22. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2004; 364: 937–952.

23. Conroy R, Pyorala K, Fitzgerald A et al. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

24. O’Leary DH, Polak JF, Kronmal RA et al. Karotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22

25. Budoff MJ, Achenbach S, Blumenthal RS et al. Assessment of Coronary Artery Disease by Cardiac Computed Tomography, A Scientific Statement From the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation, 2006; 114: 1761–1791.

26. Naghavi M, Falk E, Hecht HS et al for the SHAPE Task Force; From Vulnerable Plaque to Vulnerable Patient – Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. Amer J Cardiol 2006; 98(Suppl): 2H–15H.

27. Grundy SM, Cleenam JI, Bairey CN et al. Implication of recent clinical trials forthe National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239.

28. Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438–445.

29. Králíková E, Býma S, Cífková R et al. Doporučení pro léčbu závislosti na tabáku. Čas Lék Čes 2005; 144: 327–333.

30. Grundy SM. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31: 1149–1172.

31. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418.

32. Keech A, Simes RJ, Barter P et al. (FIELD study investigators). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849–1861.

33. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–1592.

34. Pasternak RC, Smith SC jr, Bairey-Merz CN et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567–572.

35. Pearson TA, Mensah GA, Wayne Alexander R et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and American Heart Association. Circulation 2003; 107: 499–511.

36. Danesh J, Collins R, Peto R. Lipoprotein( a) and coronary heart disease. Meta- analysis of prospective studies. Circulation 2000; 102: 1082–1085.

37. Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine lowerin and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578–1588.